Fool.com
The World's Greatest Investing Community
Results 1 - 10 of 315 : 1 2 3 4 5 6 7 8 9 Next
A Big Upgrade for Gilead Sciences
This bullish call comes from more than just one analyst.
5-Star Stocks Poised to Pop: Gilead Sciences
Market-beating returns could be written in these five stars.
Buy This Investment If You Want to Lose Money
Active management is dealt another blow.
How Much Is Management Costing You?
The mutual fund scene is bleaker than you may think.
This Just In: Upgrades and Downgrades
Needham suspends clinical trial of buying Geron.
Two Fools Featured in Barron's
Barron's looks at the success of Motley Fool Pro.
Saved by Emerging Markets. Sort Of.
GlaxoSmithKline's top line looks good, but the bottom is what counts.
Tomorrow's huge winners are out there today. The trick is finding them.
Swine Flu Doesn't Need to Save Novartis
The company is looking healthy all on its own.
It doesn't take large wads of cash to make large wads of cash investing in stocks.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK